Investigational drug · Phase 3
Vepugratinib
Also called: LY3866288
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Vepugratinib"
First trial start
2025
Dec 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vepugratinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- Receptor, Fibroblast Growth Factor, Type 3
- Carcinoma, Transitional Cell
- Neoplasm Metastasis
Approved drugs for the same conditions: Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vepugratinib" as an intervention, largest first.
Eli Lilly and CompanyEli Lilly (LLY)
NCT05614739 · 677 participants (planned) · Start Jan 12, 2023 · Primary completion Jun 2027
Drug: Vepugratinib; Pembrolizumab and 5 more · For: Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms
Sites: Tucson, Arizona; Duarte, California; Los Angeles, California · 83 sites in all
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07218380 · 450 participants (planned) · Start Dec 12, 2025 · Primary completion Oct 2029
Drug: Vepugratinib; EV and 1 more · For: Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasm Metastasis
Sites: Tucson, Arizona; Little Rock, Arkansas; Irvine, California · 276 sites in all
- A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07827612 · 161 participants (planned) · Start Dec 2026 · Primary completion Jul 2028
Drug: Vepugratinib · For: Urinary Bladder Neoplasms; Urologic Neoplasms; Receptor, Fibroblast Growth Factor, Type 3
Sites: Myrtle Beach, South Carolina
Eli Lilly and CompanyEli Lilly (LLY)
NCT07675057
Drug: Vepugratinib · For: Urinary Bladder Neoplasms; Neoplasm Metastasis; Carcinoma, Transitional Cell
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Urinary Bladder Neoplasms
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer
- MK-3120SKB410Phase 24 trials
Merck & Co. · Bladder Cancer, Advanced Solid Tumors, Malignant Neoplasm
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.